SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.800
-0.070 (-1.81%)
At close: Jun 26, 2026, 4:00 PM EDT
3.810
+0.010 (0.26%)
After-hours: Jun 26, 2026, 7:37 PM EDT
SAB Biotherapeutics Employees
SAB Biotherapeutics had 86 employees as of December 31, 2025. The number of employees increased by 23 or 36.51% compared to the previous year.
Employees
86
Change (1Y)
23
Growth (1Y)
36.51%
Revenue / Employee
n/a
Profits / Employee
-$109,428
Market Cap
290.56M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Lyell Immunopharma | 161 |
| Nautilus Biotechnology | 127 |
| Verastem | 102 |
| Lineage Cell Therapeutics | 77 |
| Immuneering | 55 |
| Cybin | 50 |
| Surrozen | 44 |
SABS News
- 3 days ago - SAB Biotherapeutics initiated with an Overweight at Barclays - TheFly
- 4 weeks ago - SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - SAB Biotherapeutics initiated with a Buy at Citi - TheFly
- 5 weeks ago - SAB Biotherapeutics initiated with a Buy at Jefferies - TheFly
- 6 weeks ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly
- 6 weeks ago - SAB Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - SAB Biotherapeutics Earnings release: Q1 2026 - Filings